22 results about "PHA binding" patented technology

The present application relates to an anti-CD3 antibody and its application. The present application develops a specific antibody molecule targeting CD3 epsilon chain, which can activate T cells by combining with CD3 epsilon on T cells. A T cell binding protein containing the CD3 antibody is further designed, which can specifically target and bind to CD3 epsilon on the surface of T cells in vivo and in vitro, so as to achieve moderate activation of T cells. The CAR lentivirus containing the T cell binding protein of the present application can induce the generation of CAR-T cells in vitro and in vivo, and the CAR-T cells have good tumor cell killing efficiency.

The present application relates to the technical field of RNA extraction, and particularly relates to a pretreatment reagent, a method and a kit for RNA purification of whole blood samples. By introducing hydrophobic DESs as the core pretreatment component, the DESs are mixed with the whole blood sample in advance, the DESs form an independent phase layer after centrifugation by using the unique physicochemical properties, and the liposoluble drug components, inflammatory proteins and pigments are selectively extracted to the hydrophobic DESs phase and the RNA is preliminarily purified; the upper water phase of the pretreatment and purification is taken and added into a lysis solution containing a chaotropic salt to fully release the nucleic acid, and DNase I is introduced for digestion. The present application combines the pretreatment of hydrophobic DESs and the digestion of DNase I, and is used in combination with PVP (targeting adsorption of residual pigments and phenolic compounds), reduces the impurities of the lysis system through the front-end pretreatment, creates a low-interference and high-efficiency purification environment for the specific binding of RNA by the magnetic beads, and forms a synergistic removal network for the interference of complex samples.

The present application relates to a kind of sgRNA targeting Plagl1 gene DMR, epigenetic editing system and its application.Specifically, the present application provides sgRNA targeting Plagl1 gene differential methylation region, which forms epigenetic editing system with dCas9-Tet1-CD fusion protein.The system is loaded in injectable type light-cured silk fibroin hydrogel, the expression of Plagl1 gene in periosteum stem / progenitor cells is accurately activated by targeted demethylation modification, thereby promoting osteogenic differentiation.The present application combines epigenetic regulation with biomaterial delivery, and provides a safe, efficient new strategy for jaw bone defect regeneration and repair.

The present application relates to the technical field of biological medicines, and particularly relates to a polypeptide for specifically blocking the interaction between PD-L1 and endogenous double-stranded RNA and a medicine. The present application provides a polypeptide for specifically binding to endogenous double-stranded RNA, which has a strong effect on the activation of innate immune genes. The polypeptide fused with a cell-penetrating peptide can competitively bind to endogenous double-stranded RNA in cells and inhibit the A-to-I editing of endogenous double-stranded RNA, thereby improving the sensitivity of tumor cells to drugs. The present application provides a new strategy for the immunotherapy of tumor patients and has a wide application prospect.

The present application relates to the field of biotechnology, in particular to a pair of mutually recognizing and combining alpha helix peptides and application thereof. The alpha helix peptide 1 has an amino acid sequence as shown in SEQ ID No. 1, and the alpha helix peptide 2 has an amino acid sequence as shown in SEQ ID No. 2. The cells are combined with each other by a pair of mutually recognizing and combining alpha helix peptides, so that the cells are arranged in a desired manner. The suitable material concentration and action time are verified; the formed cell group morphology is observed by various microscopes; two kinds of models are successfully constructed; and the improvement of cell function by adding DPH material is verified.

The application discloses a platelet antibody detection and cross matching blocking chromatography kit and a detection method thereof, wherein the kit comprises a U-shaped microwell plate, a chromatography medium for separating platelet immune complexes from non-cell particle components under the action of centrifugal force, freeze-dried platelets, a platelet diluent, a platelet fluorescent staining solution comprising fluoresceinized platelet antibodies specifically labeled for platelets, biotin-labeled anti-human globulin for specifically binding with antibodies bound to the surface of the platelets, avidinized fluorescein for coupling with the biotin-labeled anti-human globulin through a biotin-avidin specific binding system, negative control serum / plasma and positive control serum / plasma. The application combines the blocking chromatography technology with a high-sensitivity flow immunofluorescence method to construct an efficient and accurate platelet antibody detection and cross matching system, which is high in specificity and sensitivity, simple in operation and stable in detection results.

Disclosed in the present invention are antifungal compounds, a preparation method therefor, and the use thereof. The compounds have the following general formula I, wherein L represents a linking moiety, referring to a small molecule fragment, and Ar represents a heterocyclic ring or a substituted heterocyclic ring. The series of compounds of the present invention can better bind to an enzyme target by means of various interaction forces, thereby exhibiting good activity; and the compounds exhibit excellent activity in both in vitro experiments and animal experiments, the activity of most of the compounds against Candida albicans being better than that of fluconazole. In addition, the series of compounds have anti-inflammatory effects while eliminating fungal infections; and compared with voriconazole, the series of compounds of the present invention can remarkably down-regulate the expression of an inflammatory factor interleukin 6.

The present application belongs to the technical field of alternative immunomodulators, and particularly relates to a preparation method of a Passiflora edulis immunomodulator for pigs and application thereof, which comprises the following steps: inoculating activated gold flower fungus into a liquid culture medium to prepare seed liquid; pretreating Passiflora edulis fruits, cutting or crushing the Passiflora edulis fruits to prepare a fermentation substrate, and adding bran and / or corn powder as an auxiliary carbon source; sterilizing the fermentation substrate; inoculating the seed liquid to perform solid or liquid fermentation; in the fermentation process, the gold flower fungus secretes an enzyme system to destroy the cell wall of the Passiflora edulis, release and convert polysaccharides and flavonoid active ingredients; and drying and crushing to obtain the Passiflora edulis immunomodulator for pigs. The immunomodulator can be added into pig feed to significantly improve the spleen index, macrophage phagocytic activity, lymphocyte proliferation capacity and serum IgG level, reduce the diarrhea rate, and promote growth performance. The present application combines the gold flower fungus and the Passiflora edulis to prepare the immunomodulator for pigs, which can be used to replace antibiotics and promote healthy pig breeding.

The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.

This application discloses a method for detecting CHI3L1 protein based on microfluidic fiber optic sensing, belonging to the field of biomedical detection technology. The method includes: providing a microstructured fiber optic sensing unit with a through-flow microfluidic channel; immobilizing a CHI3L1 protein-specific antibody on the inner surface of the microfluidic channel; injecting the sample to be tested into the channel, causing the CHI3L1 protein to be specifically captured; and achieving quantitative detection of the CHI3L1 protein by detecting the drift of fiber optic transmission spectral characteristic parameters caused by antigen-antibody binding. This invention combines microfluidics with fiber optic sensing, utilizing antibody immobilization on the inner wall of the microfluidic channel to increase the interaction efficiency between the light field and biomolecules, significantly improving detection sensitivity. It has the advantages of rapid detection, low sample consumption, and label-free operation, making it suitable for early non-invasive screening and dynamic monitoring of clinical liver fibrosis.

This invention discloses a method for preparing the soluble heat shock protein GroEL1, belonging to the field of heat shock protein preparation technology. The method includes: constructing a recombinant expression plasmid containing the groEL1 gene; transforming the recombinant expression plasmid into *E. coli* for induced expression to obtain bacterial cells containing soluble GroEL1 protein; lysing and centrifuging the bacterial cells to obtain a crude soluble protein extract; performing Ni-NTA affinity chromatography with gradient elution to obtain a GroEL1 protein eluent containing a His tag; performing ultrafiltration concentration and buffer replacement; enzymatically digesting the His tag in the replaced GroEL1 protein solution to remove the His tag, followed by gel filtration chromatography to obtain purified GroEL1 protein. This invention, by optimizing the induction temperature and time and employing a lysis method combining ultra-high pressure homogenization and low-temperature centrifugation, effectively avoids the aggregation and degradation of GroEL1 during conventional preparation processes, significantly improving the yield of soluble protein and solving the problems of low GroEL1 yield and easy precipitation and inactivation in existing technologies.

The application provides a single-domain antibody capable of binding to different serotypes of AAV, and use thereof, the single-domain antibody comprising CDR1, CDR2 and CDR3, the amino acid sequences of which are shown in SEQ ID NO. 2-4 respectively or mutants thereof. The single-domain antibody can bind to various serotypes of AAV and has high affinity activity, and can be used for affinity purification of AAV.

This invention relates to the field of biotechnology and discloses a method for detecting intact, live pathogens in samples. The invention provides a rapid detection method for intact, live pathogens based on specific immunomagnetic beads and microfluidic chips, and constructs an automated, multiplexed detection system. Its core lies in combining three key steps—"specific capture of intact pathogens," "active signal screening," and "rapid and sensitive detection"—with a microfluidic chip technology platform. This transforms the protein signal of antigen-antibody binding into a nucleic acid amplification signal, improving sensitivity and enabling direct, rapid, and accurate identification of infectious live pathogens from complex samples, thus demonstrating broad application prospects.

The application discloses application of a polypeptide in preparation of a drug for treating or relieving PTSD. The application first discovers a specific scaffold protein FRMD5 of a protein isoform, the protein isoform can form a nuclear condensate, is combined with a group of unique protein partners (rich in GR chaperone cycle components and transcriptional co-regulators), and can reshape nuclear translocation, transcriptional activity and target gene expression of GR. An interfering peptide is designed aiming at the target, can regulate the nuclear translocation, transcriptional activity and target gene expression of GR, and can relieve stress response of a mouse. The application can be applied to preparation of a drug for treating or relieving PTSD.

The invention relates to a method for the qualitative determination of peripherin, comprising the combining and incubating of a diluted sample with a first antibody conjugate comprising a first antibody bound to a solid phase and a second antibody conjugate comprising a biotinylated second antibody, the removal of the liquid phase and the initiation and measuring of a colour reaction. The invention also relates to a quantification of peripherin in a sample by means of a calibration curve, to the creation of a calibration curve and to a kit for peripherin determination.

Provided are isolated or recombinant monoclonal antibodies that bind to 4-1BB. In some cases, the antibodies of the embodiments can be used for the detection, diagnosis, and / or therapeutic treatment of human diseases, such as cancer.

This invention discloses BacPROTACs targeting dihydropteranoic acid synthase, their preparation method, and their applications, belonging to the fields of medicinal chemistry and anti-infective drug technology. The BacPROTACs have the structure shown in Formula I, II, or III, and are composed of a DHPS inhibitor fragment, a linker group, and a phosphorylated arginine (pArg) fragment. The pArg fragment, as a functional group capable of interacting with the bacterial ClpCP protease system, is coupled to a DHPS inhibitor through linkers of different types and chain lengths, resulting in bifunctional molecules possessing both DHPS binding and ClpCP recruitment capabilities. These compounds can recruit the ClpCP protease system while binding to DHPS, thereby inducing or promoting DHPS degradation, reducing target protein levels, and expanding the pharmacodynamic mechanism of DHPS-targeted drugs. Compared with existing DHPS inhibitors that mainly rely on reversible inhibition, this invention provides a new technical solution for the development of antibacterial drugs through a design strategy combining inhibition and targeted degradation. These compounds can be used to prepare antibacterial drugs.

The invention relates to the technical field of hydrogel preparation, and discloses a preparation method of DNA hydrogel, which comprises the following steps: a, using plasmid as a template, and melting double strands of the plasmid template through alkaline denaturation; b, adding a random primer, enabling the plasmid template to be combined with the random primer in a renaturation process, and producing a large amount of double-stranded DNA with an ultra-long chain length and a high-branch topological structure as a DNA hydrogel precursor through hyper-branched rolling circle replication amplification; c, adding a dehydrating agent into the DNA hydrogel precursor solution, and realizing self-assembly by utilizing dense physical entanglement among double-stranded DNA molecules under the induction of the dehydrating agent to form a DNA aggregate; and d, collecting the DNA aggregate, drying the DNA aggregate to remove the residual dehydrating agent, resuspending the DNA aggregate in a buffer solution to enable the DNA aggregate to absorb water and swell, and finally forming the DNA hydrogel with a stable structure. According to the invention, the design and preparation process of the DNA hydrogel can be greatly simplified, the availability of the DNA hydrogel is improved, and the transformation of the DNA hydrogel from basic research to practical application is promoted.

The invention provides dual-specific antibodies and methods for manufacturing and using these antibodies. In general, the dual-specific antibodies are generated by identifying a monospecific antibody with electrostatic or hydrophobic light chain variable region (VL) residues and altering the nucleic acid sequence encoding one or more solvent-accessible residues in the antibody's VH, either alone or in combination with altering the nucleic acid sequence encoding the antibody's VL. The altered VH and VL are expressed, and dual-specific antibodies or antigen-binding fragments are selected from them. Examples of dual-specific antibodies and methods for using the antibodies are also provided.

This invention provides a method for detecting antibodies, comprising: providing a test strip for detecting antibodies, the test strip comprising a label pad, a sample pad, a test pad, and an absorbent pad sequentially overlapped from upstream to downstream on a base card; the test pad comprising a first test line and a second test line, the first test line being downstream of the second test line; the label pad comprising a marker that binds to the antigen; adding a sample to be tested to the sample pad of the test strip; adding a buffer solution to the test strip, causing the marker on the label pad to be released and flow into the test pad; the marker on the label pad reaching the test pad at a time later than the time the added sample reaches the test pad. The test strip of this invention has a simple structure, strong anti-interference ability, and high detection sensitivity.